DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award | HT942525ALSRPTIA

Opportunity Information: Apply for HT942525ALSRPTIA

The FY25 Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) is a discretionary grant opportunity administered by the Department of the Army through USAMRAA (Funding Opportunity Number: HT942525ALSRPTIA). It is designed to push forward new therapeutic directions for ALS by funding early-stage, innovative concepts that are intentionally high-risk but potentially high-reward. The core focus is drug or therapy discovery, with an emphasis on ideas that could open up fresh avenues for treatment rather than incremental extensions of well-established approaches.

This award mechanism is geared toward hypothesis-driven studies that can produce interpretable results and generate preliminary data, even if the project begins without strong prior evidence supporting the hypothesis. In other words, applicants are not required to have extensive preliminary datasets to be competitive, as long as the proposed experimental strategy is sound and capable of delivering clear, meaningful outcomes. Preliminary data can be included, but the program signals that proposals should stand on the strength of the rationale, design, and feasibility of the approach, not on how much data the team already has in hand. The intent is to create a runway for novel therapeutic concepts that might otherwise struggle to attract funding at this early stage.

The funding instrument type is a grant under the Science and Technology and other Research and Development activity category, associated with CFDA number 12.420. Eligibility is listed as unrestricted, indicating that a broad range of applicant organizations may apply, rather than limiting submissions to a narrow set of institution types. The opportunity anticipates making about 11 awards. The posted original closing date is August 27, 2025, and the opportunity record was created on April 18, 2025. The listing does not provide an award ceiling amount in the supplied source text.

Overall, this program is best understood as a seed-stage translational research award for ALS therapeutics: it aims to catalyze unconventional or cutting-edge therapeutic ideas, support rigorous early testing, and produce the kind of preliminary evidence that can justify larger follow-on studies and more advanced preclinical development.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2025-04-18.
• Applicants must submit their applications by 2025-08-27. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 11 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942525ALSRPTIA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: